Dr. Jeffrey Lin, DO

Dr. Lin practices at American Medical Group in Fort Walton Beach, Florida.

Dr. Lin's NPI, 1639622665, was assigned on July 26, 2016. Dr. Lin graduated from Pcom in 2016. Dr. Lin holds Florida license OS17605.

Dr. Lin's primary practice is American Medical Group, at 917 Mar Walt Dr, Fort Walton Beach, FL 32547 in Okaloosa County. The practice phone is (850) 862-3979.

Dr. Lin's primary practice is American Medical Group in Fort Walton Beach, Florida. Dr. Lin is also affiliated with HCA Florida Fort Walton-Destin Hospital. The medical group on file is American Medical Group. Dmand AI also links Dr. Lin to 4 more hospitals, 1 group practice or clinic, 1 home health agency and 1 hospice, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lin practices, 8 sites in all. Vendor and product names are available with a free account.

Infectious disease is Dr. Lin's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dr. Lin is board certified in internal medicine by the AOA Board of Internal Medicine. Dr. Lin is licensed in Florida.

Dmand AI lists acute sinusitis, acute skin infection, bronchitis, endocarditis, facial skin infection, hepatitis c, hiv/aids and immune deficiency disease among the conditions Dr. Lin treats.

CMS data shows 3,012,728 Medicare services from Dr. Lin across 50 procedure codes in 2024, for 1,440 Medicare patients. Medicare paid $2,983,650 for them.

CMS counts 1,440 Medicare patients who saw Dr. Lin in 2024. The largest group is 75 to 84, with 517 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 16% are also on Medicaid. Their average risk score is 2.37, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lin's median patient age at 70, with 55% women.

In 2024, Dr. Lin wrote 476 Medicare Part D claims for 170 patients. 86% of them were for generic drugs. CMS names the drug for 329 of them, across 13 drugs with 11 or more claims each, at $43,600 in total drug cost. In 2023, CMS named 432 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Lin for performance year 2024, reported as part of a group. Dr. Lin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Lin as offering telehealth. CMS counts 594 procedures of removal of tissue by Dr. Lin, more than 97% of the clinicians it reports for that procedure.

Removal of skin lesions: 1 to 10 procedures (CMS shows small counts as a range)

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 3 papers to Dr. Lin, published from 2018 to 2024. Dr. Lin's most frequent co-authors are Ivan Augusto Arenas, MD, PhD, Mark Stephen Diamond, MD, PhD and Sofia Horvath, MD.

CMS Open Payments shows 123 general payments to Dr. Lin from 21 drug and device companies from 2021 to 2025. Speaker and faculty fees make up the largest share, 74% of the total. Melinta Therapeutics, Inc. paid the most, $9,485.

Dr. Lin graduated from Pcom in 2016.

Dr. Lin is in network with 15 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 11. Check the plan with the practice before a visit.